Ceftolozane/tazobactam: New treatment option for severe infections, but no proof of superiority

(Institute for Quality and Efficiency in Health Care) Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority New antibiotic broadens the treatment options for severe infections and resistances. However, there is no evidence of advantages or disadvantages in comparison with other antibiotics.